Consolidated Statement Of Income

Oncolys BioPharma Inc. - Filing #7310662

Concept 2024-01-01 to
2024-06-30
2023-01-01 to
2023-06-30
Consolidated statement of income
Statement of income
Net sales
31,384,000 JPY
63,038,000 JPY
Cost of sales
JPY
32,433,000 JPY
Operating expenses
Operating expenses - general
Remuneration for directors (and other officers)
51,291,000 JPY
48,486,000 JPY
Operating expenses
Selling, general and administrative expenses
824,755,000 JPY
931,594,000 JPY
Operating expenses
Ordinary profit (loss)
-752,997,000 JPY
-867,441,000 JPY
Gross profit (loss)
31,384,000 JPY
30,604,000 JPY
Operating profit (loss)
-793,371,000 JPY
-900,989,000 JPY
Net sales
General and administrative expenses
Salaries
Operating expenses
Research and development expenses
523,975,000 JPY
636,952,000 JPY
Extraordinary income
JPY
136,000 JPY
Non-operating income
49,593,000 JPY
35,765,000 JPY
Dividend income
5,000 JPY
3,000 JPY
Interest income
1,047,000 JPY
533,000 JPY
Cost of sales
Non-operating income
Other
22,000 JPY
177,000 JPY
Selling, general and administrative expenses
Non-operating expenses
Interest expenses
2,185,000 JPY
1,781,000 JPY
Other
73,000 JPY
JPY
Non-operating expenses
9,219,000 JPY
2,217,000 JPY
Share issuance costs
2,466,000 JPY
JPY
Gross profit
Profit (loss) before income taxes
-752,997,000 JPY
-867,305,000 JPY
Extraordinary income
Gain on sale of non-current assets
JPY
136,000 JPY
Income taxes - current
1,871,000 JPY
1,457,000 JPY
Income taxes
1,871,000 JPY
1,457,000 JPY
Profit (loss)
-754,868,000 JPY
-868,762,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.